SomaLogic, Inc. (SLGC): Price and Financial Metrics

SomaLogic, Inc. (SLGC): $2.34

0.00 (0.00%)

POWR Rating

Component Grades








Add SLGC to Watchlist
Sign Up

Industry: Medical - Services




#65 of 69

in industry

SLGC Price/Volume Stats

Current price $2.34 52-week high $3.79
Prev. close $2.34 52-week low $1.92
Day low $2.24 Volume 1,182,751
Day high $2.38 Avg. volume 1,018,939
50-day MA $2.19 Dividend yield N/A
200-day MA $2.61 Market Cap 440.09M

SLGC Stock Price Chart Interactive Chart >


  • SLGC scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.11% of US stocks.
  • SLGC's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • SLGC's current lowest rank is in the Stability metric (where it is better than 12.04% of US stocks).

SLGC Stock Summary

  • SLGC's went public 2.59 years ago, making it older than only 8.8% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for SOMALOGIC INC is higher than it is for about just 0.33% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.14 for SOMALOGIC INC; that's greater than it is for only 10.91% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SOMALOGIC INC are MXCT, SMRT, WISH, BASE, and PHR.
  • To dig deeper into the stock's financial statements, go to SLGC's page on browse-edgar?action=getcompany&CIK=0001837412.

SLGC Valuation Summary

  • SLGC's price/sales ratio is 4.2; this is 121.05% higher than that of the median Healthcare stock.
  • SLGC's price/earnings ratio has moved up 2.9 over the prior 31 months.

Below are key valuation metrics over time for SLGC.

Stock Date P/S P/B P/E EV/EBIT
SLGC 2023-09-22 4.2 0.8 -3.0 -0.5
SLGC 2023-09-21 4.2 0.8 -3.0 -0.5
SLGC 2023-09-20 4.2 0.8 -3.1 -0.5
SLGC 2023-09-19 4.3 0.8 -3.1 -0.6
SLGC 2023-09-18 4.2 0.8 -3.0 -0.5
SLGC 2023-09-15 4.3 0.9 -3.1 -0.6

SomaLogic, Inc. (SLGC) Company Bio

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-offrate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company's solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions; and facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SLGC Latest News Stream

Event/Time News Detail
Loading, please wait...

SLGC Latest Social Stream

Loading social stream, please wait...

View Full SLGC Social Stream

Latest SLGC News From Around the Web

Below are the latest news stories about SOMALOGIC INC that investors may wish to consider to help them evaluate SLGC as an investment opportunity.

SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market

DNA Link will bring the power of the largest proteomics platform available to their biomarker discovery and drug development workBOULDER, Colo. and SEOUL, Korea, Sept. 19, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its partnership with DNA Link, an innovator in personalized and precision medicine, to offer the 7,000-plex SomaScan® platform to their customers. DNA Link will be the first SomaLogic authorized site in Korea.

Yahoo | September 19, 2023

SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors

SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types.BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- In a new paper published in Nature's Scientific Reports, researchers at SomaLogic Inc. studied the value of protein biomarkers in the early detection of cancer and the stratification of cancerous tumors. The research team identified 15 blood proteins shared among all cancer types as well as models to stratify tumor types. The goal of this research was to i

Yahoo | September 12, 2023

SomaLogic expands agreement with Novo Nordisk to 2025

Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseasesBOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan® proteomics platform in drug researc

Yahoo | September 5, 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported Earnings, And Analysts Cut Their Target Price

SomaLogic, Inc. ( NASDAQ:SLGC ) just released its quarterly report and things are looking bullish. Revenues and losses...

Yahoo | August 18, 2023

SomaLogic Reports Second Quarter 2023 Financial Results

Revenue of $20.5 million, an increase of 45% year-over-yearCash and investments of approximately $474 million, a strong capital position to fund current and future business initiativesReiterating full year 2023 revenue guidance and operating expense targetManagement to host conference call today at 4:30pm ET BOULDER, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended June 30, 2023. “Our second quarte

Yahoo | August 14, 2023

Read More 'SLGC' Stories Here

SLGC Price Returns

1-mo 16.42%
3-mo 4.46%
6-mo -8.24%
1-year -21.21%
3-year N/A
5-year N/A
YTD -6.77%
2022 -78.44%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!